Baofa Yu, M.D. Chief Physician in China, Adjunct Professor at University of Texas (El Paso) (2016) and Adjunct Professor at Western University of Health Sciences (2016). He graduated from Peking Union Medical College (Peking Union Medical College) in 1988. He was a post-doctoral fellow at UCSD from 1990 to 1991, Salk from 1992 to 1993, Assistant Adjunct Professor, UCSD from 1994 to 1998. In the United States, he was mainly engaged in the research of cancer drug carrier drug delivery and tumor molecular biology. He invented the new concept of using tumor tissue as a sustained release system of anticancer drugs and the treatment method of sustained release reservoir, which has clinical application value, it is also called ultro-Minimum incision personalized intratumoral chemoimmunotherapy (UMIPIC). In 1998, he returned to China and founded Shandong Baofa Research Institute and Taimei Baofa Cancer Hospital in Dongping rural area with technological investment, and served as the chairman of Shandong Baofa Cancer Treatment Co., LTD., and later established Jinan Baofa Cancer Hospital (2004). Dongping Baofa General Hospital (2011), Beijing Baofa Cancer Hospital (2013) and Immuno Oncology Systems, Inc. This UMIPIC is safe, easy to operate, and reproducible with good benefit for all solid tumor. Today this therapy is accepted to “Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer” (Trial) (7th edition), jointly formulated by the Chinese Anti-Cancer Association, the National Clinical Medical Research Center for Radiology and Therapy, and the National Interventional Medicine Innovation Alliance, Journal of Clinical Radiology, volume 43, number 19, 2024, 1636-1648.
He has published more than 60 papers about this therapy in Nature:Scientific Report, Journal of Cancer, Cancer letter, Cytokin and Growth Factor Reviews, Nature Cancer (under review), J Basic Clin Pharma, J Immunological Sci, Japanese Journal of Gastroenterology and Hepatology, Novel Approaches in Cancer Study, Academic Journal of Engineering Studies, Nov Res Sci, Journal of Hepatocellular carcinoma, lung Cancer: Target and Therapy, Journal of Liver Research, disorders & therapy, Chinese Journal of Chest,Proc.Natl.Acad.Sci.USA, Pancreas and other journals and many post papers participated in AACR and ASCO meeting.
Our major contribution is that sustained-release therapy integrates the advantages of chemotherapy and immunotherapy, and for the first time, the two have been combined and applied to intratumoral therapy through intervention. It integrates local and global treatment, and increases the concentration and time of drug action through sustained release of drugs within the tumor, which not only plays a local anticancer effect of chemotherapy drugs, but also takes into account the role of systemic immunotherapy, thus making up for the shortcomings of other therapies, providing new ideas and approaches for cancer treatment, especially for middle and advanced tumors, especially for reducing tumor recurrence and inhibiting tumor The transfer has very important value; UMPIC therapy has the advantage of using tumor as antigen source and autologous vaccine, which is also in line with the development trend of Personalized Medicine. And applied to the clinic, hapten combined with chemotherapy drugs for sustained release treatment of pancreatic cancer primary focus, while inducing distal effect, the essence of which is to induce immune response, T-cell-related CD4, CD8, DC, T and NK cells, and B-cell-related tumor autoantibodies: Antibodies to P53, P16, Cmyc, Zeta, IMP1, Koc, Survivin, p62, HCC1 and other oncogenes, this is the first time to find that T and B are involved in the immune response, and the clinical functions of the distal effect and this therapy was selected for “Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer” (Trial) (7th edition) jointly formulated by the Chinese Anti-Cancer Association, the National Clinical Medical Research Center for Radiology and Therapy, and the National Interventional Medicine Innovation Alliance was published at
Journal of Clinical Radiology, volume 43, number 19, 2024, 1636-1648.